Hoppa till innehåll
/Ekonomisk utvärdering

Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metforminin Patients with Type2 Diabetes Mellitus in Mexico

Neslusan C, Teschemaker A, Johansen P, Willis M, Valencia-Mendoza A and Puig A

The validated IHE model (Economic and Health Outcomes [ECHO]-T2DM) was used to estimate the cost-effectiveness of canagliflozin versus sitagliptin for the treatment of type 2 diabetes mellitus (T2DM) as an add-on to metformin in Mexico. Data from a head-to-head, phase III clinical trial were used to simulate outcomes and resource use over 20 years. The results showed that canagliflozin (both 100 and 300 mg) was likely to be cost-effective versus sitagliptin in patients with T2DM who have inadequate glucose control on metformin, from the perspective of the Mexican health care system.

Read more

Value in Health Regional Issues 2015; 8: 8-19
DOI: https://doi.org/10.1016/j.vhri.2015.01.002